Maximizing Patient Outcomes Through IV Iron Therapy and Appropriate Iron Measures

A CME Symposium at the Renal Research Institute
7th International Conference on Dialysis: Advances in ESRD 2005; New Orleans, January, 2005.
Access to this program is free but HDCN free zone registration is required.
Independent Benefits of IV Iron: Beyond Raising Hgb Levels
Rajiv Agarwal, MD
Considerations in Iron Measures:
What Is an Appropriate Serum Ferritin Level?

Daniel Coyne, MD


After participating in this activity, participants should be able to:
Illustrate the importance of IV iron and EPO in effective anemia treatment
Describe the benefits of IV iron therapy independent of EPO therapy
Summarize the current iron markers used to determine iron status
Discuss K/DOQI recommendations for treating iron-deficient patients based on serum ferritin levels
Describe the clinical implications of an elevated serum ferritin level

Rajiv Agarwal, MD
Associate Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Daniel Coyne, MD
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Medical Education Resources, Inc. Medical Education Resources, Inc. is accredited by the ACCME to sponsor continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity.

Medical Education Resources, Inc. designates this educational activity for a maximum of 1.5 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Post-test and Evaluation Form are at this link, but you must listen to all four talks from this symposium prior to completing the test.

To earn CME credit for viewing the lectures, please print and complete the CME Posttest questions and return with the completed Evaluation Form to Medical Education Resources, Inc. via fax at (303) 798-5731 or mail at 1500 West Canal Court, Suite 500, Littleton, Colorado 80120-5617.

This program is intended for clinicians who work in the area of nephrology.

All faculty participating in continuing medical education programs are expected to disclose to the program audience any real or apparent conflict of interest related to the subject under discussion. The faculty disclosure information is as follows:
Rajiv Agarwal, MD, has received grant/research support from Watson Pharma, Inc. and is a consultant, Speakers Bureau participant, and Advisory Board member for Watson Pharma, Inc.
Daniel Coyne, MD, has received grant/research support from Watson Pharma, Inc. and is a consultant and Speakers Bureau participant for Watson Pharma, Inc.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by FDA. Medical Education Resources, RRI, HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
All of the agents overviewed in this virtual symposium will be discussed in the context of uses for which they have not been approved by the FDA.

This educational activity is supported by an educational grant from Watson Pharmaceuticals Inc.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.
These lectures were not an official part of the Renal Research Institute's 2005 Meeting Program.